2021 Faculty

Giovanni Abbadessa MD, PhD
Head of Oncology Early Development
Sanofi

Head of Oncology Early Development since Sep 2019; Head of Isatuximab Non-myeloma Development since Apr 2017.   ArQule (2009-2017): VP Oncology Clinical Development, Research, Medical Affairs.   Ziopharm (2007-2009): Sr Dir Onco Clin Dev. Worked hands-on on IO antibodies, TKIs, chemos. Worked on solid tumors, hematological malignancies, and rare diseases in FIH, Ph1, RCT Ph2, Ph3 studies. Led teams of biologists, clinicians, in research, development, operations. Led partnerships, Joint Steering & Development Committees, relations with KOLs, advisory boards, investigator meetings. Supported Business Development, Investor Relations, Board management. Authored 40+ peer-reviewed articles, 70+ oral/poster presentations.

Fluent in English, Italian, Spanish, basic in French. Founded and run a local nonprofit Saturday Italian school for children and parents, and a cultural Boston association. Sit in board of a local school and of an elected committee to represent Italians in Boston. Love skiing, sailing, travelling, tennis.

Omer Abdullah, M.D.
Head of Medical Advisors in the Americas Clinical Study Unit (CSU)
Sanofi

Omer Abdullah, M.D. is Head of Medical Advisors in the Americas Clinical Study Unit (CSU), leading the CSU medical team across all therapeutic areas.  Omer first joined Sanofi in 2006 and has been a Medical Advisor and a Clinical Study Director prior to his current role. Before joining Sanofi, he practiced as an Internist, holding clinical faculty appointments and served as an Investigator for multiple clinical trials. Omer is currently leading the Inclusion and Diversity in Clinical Trials team and represents R&D at the North America I&D Executive Council. In addition, Omer is also working on improving data driven decisions in trial operations.

Murray Aitken, MBA
Senior Vice President at IQVIA and Executive Director of the IQVIA Institute for Human Data Science
IQVIA

Murray Aitken is a senior vice president of IQVIA and Executive Director of the IQVIA Institute for Human Data Science. The Institute undertakes independent research for publication, drawing upon the resources of IQVIA and focuses on improving understanding of critical healthcare issues around the world, including the role of medicines in patient care, the disruptive impact of technology, productivity in research and development, and the value of information in improving decision-making. In his role, Murray directs the research agenda and co-authors reports, while also engaging externally with a broad range of healthcare decision-makers in the public and private sectors as well as the media. Murray holds an MBA, with distinction, from Harvard University and a Master of Commerce degree from the University of Auckland in New Zealand.

Anna Argyris, MSHS, CCRP
Director, Site Solutions
Veeva Systems

 

Jane K. Bentley
VP, Business Strategy, Oncology & Haematology 
Syneos Health 

 

Jimmy Betchel, MBA
Vice President, Site Engagement
Society for Clinical Research Sites (SCRS)

 

Dave Billiter, MBA
Founder, Deep Lens
Deep Lens

Dave is a healthcare and life sciences executive with experience in general management, strategy, operations and business development. Prior to co-founding Deep Lens, Dave spent 20 years in both large corporations and start-ups, most notably, the Research Institute at Nationwide Children’s Hospital where he led the innovative technology development that supported the institute.

Stacey Brown, CCRP
Clinical Research and Data Manager
Northside Hospital

Stacey Brown has spent the past 20 years working in Hematologic Malignancy Research including 7 years at a large academic institution and 13 years with Northside Hospital as the Clinical Research Manager for the Bone Marrow Transplant and Leukemia Programs. Stacey is extremely experienced in clinical trial start up from first in human studies to the introduction of Cellular Therapy studies at Northside Hospital where the goal is to provide quality, cutting edge research to patients and clean, accurate data to sponsors.  Stacey is part of the quality leadership team for the BMT/Leukemia Programs and is also responsible for the overall data reporting to CIBMTR.  Stacey is been certified by the Society for Clinical Research Professionals since 2004.

 

Bree Burks, RN, MSN
VP of Strategy, Site Solutions
Veeva Systems

Healthcare administrator and former ICU nurse who is passionate about enhancing treatment options for patients through clinical trials research. 

Derek Burns, PICP
Owner, Coach, Nutrition Coach & Transformation Specialist
AfterBurn Sports and Performance
Navy Veteran

Derek Burns is a Gulf War and operation Deliberate Force Navy Veteran who has been an athlete all of his life. Derek began his personal training career 14 years ago, sharing his love for personal growth that encompasses area of the physical, mental and spiritual with thousands of clients. He started his own company “AfterBurns Sports and Performance” eleven years ago and has been transforming the lives of many ever since.

Derek is BioSignature practitioner, PICP Level 1 Coach, Nutrition coach and Transformation Specialist. He was also a competitive body builder for 5 years and has been helping coach and prepare many competitive body builders, male and female. Living life by the mantra “Solid. Soulful. Substance. Strength”, he centers not only his life around God but focuses on a holistic approach when working with clients. Helping them to not only look better on the outside but feel better on the inside. He believes that the client is like art and he is the artist. “A coaches work is shown in and through his clients results”, says Coach Burns.

He has been featured and written articles for three publication Thrive Magazine, Huffington Post and Northern Virginia Magazine. Derek has also been a guest trainer and guest speaker for events such as Jack N Jill of Loudon County Health Fair, Delta Sigma Theta Fairfax Chapter Health Fair, Word of Life Church Health and Fitness and Sponsored Many Fitness and Cooking Demos in the Northern Virginia Area.  Derek is also the official personal trainer and fitness expert for the Tigerlily Foundation’s Pure Cat Initiative, where he hosts weekly classes with cancer patients, caregivers and loved ones nationally and globally.  Giving his clients what they want but showing them what they need, because ultimately “RESULTS DRIVE MOTIVATION’”

 

Jenine Caulkins
Vice President, Head, Oncology, Global Clinical Project Management
Bayer

I have 30 years of pharmaceutical industry knowledge specializing in clinical development research trials ranging from phase I-IV studies. My primary focus in the last 22 years has been in the Oncology therapeutic area. My pharma knowledge includes 15 years of working at Pfizer in Clinical Development and Development Operations focusing on Central Nervous System, Cardiovascular and Oncology. For the past 15 years at Bayer, I have been working in Oncology, Cardiovascular, and NOHI (Neurology, Ophthalmology, Hematology and Immunology) in Clinical Development and Clinical Project Management.

 

Jennifer Clauson, MHA
Director of Clinical Research Operations
Tempus Labs

Clinical Research Leader and Change Agent who builds financially successful, scientifically significant and prominent programs by increasing volumes, quality and efficiency. Trusted by the C Suite to bring business financial acumen and return on investment into the research enterprise. Hires the right people and inspires a high performing team that exceeds its own expectations. Understands clinical and scientific principals which inspires trust and engagement with Principal Investigators, clinicians and study sponsors. Therapeutic areas of expertise include hematology & oncology, neurosciences and infectious diseases. 

Danielle Coe
Founder & CEO
Black Women in Clinical Research

I am an experienced Clinical Research Professional who is bringing diversity and much-needed change to one of the most critical industries. I have helped many professionals increase their reach and opportunities through Black Women in Clinical Research (BWICR) and Black Men in Clinical Research (BMICR). Presently, the organization has over 2,000 active members. The mission is to educate, empower, support, and help Black women and men thrive in the clinical research industry. I earned a Bachelor of Science with a focus in Biology/Biological Sciences from Clark Atlanta University.

During my career, I have developed an imperative relationship with the White House and their HBCU Initiative to ensure that key information reaches students. I have been selected to participate in the Detroit Stem Entrepreneurial Excellence Program (STEEP), guiding me to become stronger as a Black woman and conquer the challenges I face as an entrepreneur and professional. Through a unique partnership with the Association of Clinical Research Professionals (ACRP), all my organization’s members will receive the exclusive opportunity to connect with hiring managers, HR representatives, and industry experts who will share their perspectives on various career-related tools and resources. It was an extreme honor to be selected for the ACRP Diversity Council as well. Lastly, I was a speaker on the Diversity Network forum titled, “Can Role Models Really Make a Difference?” That resulted in BWICR becoming an ambassador for the Diversity Network. Anything that I obtain and learn will always benefit others. I am excited to continue to grow and learn so I can impact the world.

Jackie Cole, MS
Manager, Site Engagement
Lilly

Jackie is an experienced and energetic clinical development professional – 20 years and still innovating! She is the Manager and mentor of a great group of field-based clinical development consultants. Additionally, Jackie is skilled in clinical research, strategy and business operations; primarily oncology focused. Jackie is driven to ensure business partners keep the fire alive to deliver new medicines to patients. 

Dana Deighton
Esopohageal Cancer Survivor
Patient Advocate

Dana Deighton, an esophageal cancer survivor, shares her diagnostic odyssey of false starts and life-threatening detours.

Deighton had always been healthy—she didn’t smoke, didn’t drink and exercised every day. Then came a joint pain that wouldn’t go away, visits to numerous doctors, a series of misdiagnoses, invasive tests, and growing symptoms. The correct diagnosis of stage 4 esophageal cancer “was not the diagnosis anyone wants.” But she refused to accept physicians’ recommendations for palliative care as a solution.

She describes her persistent advocacy to convince doctors to consider her as an individual different from expectations and generalizations. She asked the hard questions and had the hard discussions, resulting in an outcome better than expected.

She recommends physicians and patients do the homework, energetically collaborate and consider the individual patient in the quest for a solution. “Don’t be a passive patient.”

Dana Deighton works for the online patient community provider Inspire.com that helps connect patients with others experiencing the same disease, for a wide variety of diseases and over 4 million members.  She also serves as an Executive Board Member of the Esophageal Cancer Action Network (ECAN), is a patient representative on the Locally Advanced Esophageal Cancer Guideline Panel for the American Society of Clinical Oncology (ASCO), a member of NCI Patient Advocate Steering Committee and NCI Esophago-Gastric Task Force and serves on the Esophageal and Stomach Cancer Project Patient Advisory Committee, a project led by the Broad Institute of MIT and Harvard. She lives outside of Alexandria with her husband and three teenagers.

Shelley Douros
Director of Product – Clinical Trial Planning & Budgeting
Medidata Solutions, a Dassault Systèmes company

Shelley Douros is Director of Product, Product Management at Medidata Solutions, focusing on Clinical Trial Planning & Budgeting.  Shelley has over 20 years of experience dedicated to cross-functional collaborations specific to clinical trial budgeting and forecasting, business operations, outsourcing, and investigator budget development and negotiations.  Shelley has spearheaded the creation of financial lifecycle platforms for both sites and sponsors.  She has served as a speaker and chair at numerous industry conferences and has authored multiple published articles.  Shelley has a passion for uncovering pain points and identifying strategic solutions that lead to faster, effective, and mindful patient care.    

Molly Downhour, MHA BSN NEA-BC OCN CCRC
National Director Clinical Research 
Medix™

Molly has over 20 years of healthcare experience with specialization in oncology, research, and health care administration. Molly earned her bachelors of nursing and master of health administration as well as achieved and maintained her nurse executive advanced, oncology nurse, and clinical research coordination certifications. As a former director of a leading phase I
clinical trial site, she has proven ability to streamline processes resulting in improved clinical operational efficiencies, financial gain, and employee and patient satisfaction. Now Molly shares her passion, experience, and expertise with sites as the executive director for Medix Clinical Research.

Samuel Dychter, MD
Clinical Program Leader
Pfizer

Physician with international life science/healthcare experience, comprising 20 years of medical and drug development in clinical study design/execution, pharmacovigilance, medical affairs, and business development. Therapeutic area expertise in oncology, immunology, vaccines, drug delivery and have led multiple teams for product regulatory approvals.

Jeffery Edenfield, MD 
Medical Director
Prisma Health

Dr. Edenfield earned his medical degree from the University of Miami in Florida. He completed his internship, residency and fellowship at Walter Reed Army Medical Center in Washington, DC. Dr. Edenfield also completed a research fellowship in Hematologic Malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He recently completed his active duty service obligation as Chief of Oncology at Womack Army Medical Center in North Carolina. Dr. Edenfield is board certified in Medical Oncology, Hematology and Internal Medicine. Dr. Edenfield received his certification in Hospice and Palliative Medicine in February 2006. Dr. Edenfield is the medical director for the Institute for Translational Oncology Research, which includes conduct and oversight of phase I and first-in-human clinical trials for new cancer medications as well as management of the Biorepository Services at GHS Cancer Institute.

Mark Fleury, PhD
Principal, Policy Development, Emerging Sciences
American Cancer Society Cancer Action Network (ACS CAN)

Mark Fleury is a policy principal for the American Cancer Society Cancer Action Network (ACS CAN). He specializes in research, drug development, and regulatory policies along with other science and technology-related projects. He led a coalition in 2016 that authored a landscape report on drug development challenges in pediatric cancer, and led another coalition in 2017 that created a report and recommendations focused on overcoming cancer clinical trial enrollment barriers. In addition to his ACS CAN experience, Mark’s policy work includes time as a Capitol Hill legislative advisor focusing on healthcare reform, and work at the American Association for Cancer Research (AACR). He holds a PhD in bioengineering from the Ecole Polytechnique Federale de Lausanne in Switzerland.

Peter Fredette
Oncology Strategic Site Solutions Director
IQVIA

Peter Fredette has 20 years of experience in the drug development industry, including pre-clinical toxicology and all phases of clinical research. He is most experienced in oncology but has worked across a number of other therapeutic areas. Peter’s current responsibilities include site strategies for global and domestic oncology trials and, creating and implementing strategies to improve quality and accessibility of clinical trials for cancer patients around the world. Prior to this, Peter has held a variety of roles at IQVIA over the last 17 years, including trial monitoring, project management, and supporting CRO-Site relations and thought leader engagement.

Jenny Hahn
Sr. Realization Project Manager
Roche

Jenny Hahn is a Clinical Operations Leader with over 20 years of experience in clinical development across all Phases. Although the majority of her work the last 10 years has been focused on oncology research, she has broad therapeutic area experience including rheumatology, endocrinology, ophthalmology, gastroenterology, and hematology. She started her career as a research assistant at a university hospital ordering records which came in bound volumes, data entering 4 part NCR CRFs and blinding imaging films with a sharpie for submission to the sponsors. In the intervening years, she has been a CRA, a Project Manager at a CRO, a Global Study Lead and an Operations Program Leader. She is currently a Senior Realization Project Manager at Genentech within Product Development Industry Collaborations and is serving as the Roche Program Lead for Transcelerate.  

Zach Hales
Associate Director, Product Management
Greenphire

Zach Hales is a driven solutions provider with more than a decade of experience revolutionizing the manufacturing, payments and software landscapes. As a Product Manager at Greenphire, Zach is responsible for ensuring the business strategy and software development consistently evolve to meet market demand while working closely with clients to facilitate change. Exceeding customer value in the clinical research continues to be his primary focus in building Site Centricity and Patient Convenience.

Prior to joining Greenphire, Zach was responsible for managing Crane Payment Innovations’ (CPI) flagship solution, globally, in the Casino Gaming, Retail and Financial Services spaces.

Sharon Hanlon, MSN
Head of Clinical Trial Engagement & Enrollment
Bristol-Meyers Squibb

Sharon Hanlon is Head of Engagement & Enrollment at Bristol-Myers Squibb (BMS). Throughout her 19 years at BMS, Sharon has held clinical development positions of increasing responsibility from Line Management to Project Management across multiple therapeutic areas including cardiovascular, metabolics, immunology and oncology. Sharon’s team builds relationships with site and patient groups to gather insights about their disease/clinical trial experience and explore potential tactics to recruit more patient and site friendly clinical trials. Sharon received her Master of Sciences in Nursing from Thomas Jefferson University in Philadelphia, PA and prior to her career in pharma, had a career as a critical care nurse, nurse educator and research nurse coordinator at hospitals in the Philadelphia area.

Don Harder, MS
Decentralized Trials Program Lead 
Eli Lilly & Co

The next big thing: bringing the clinical trial to the patient. I’m leading Lilly’s efforts to transform clinical trials in a way that makes them more accessible and convenient for patients. Digital health, telemedicine, mobile health care, and virtualized research sites are just a few of the disruptive capabilities that we are bringing to life in order to meet patients where they are and bring the trial to them.

Jen Horonjeff, PhD, MS
CEO & Founder
Savvy Cooperative

I am a chronic illness patient by birth, a PhD by training, and an entrepreneur by necessity. I care deeply that the patient voice is heard, and fairly valued. I’m humbled to have been named one of Entrepreneur Magazine’s 50 Most Daring Entrepreneurs of 2018 for our innovative model at Savvy Cooperative, which is the first patient-owned public benefit co-op (how about that mouthful of awesomeness?!) that facilitates co-design between patients and healthcare innovators. I believe that giving patients ownership in what they help create is not only the right thing to do, it benefits everyone.

Patricia Hurley, MSc, CPHQ
Director, Strategic Research Initiatives
American Society of Clinical Oncology

Patricia Hurley, MSc, CPHQ, is the Director of Strategic Research Initiatives for the American Society of Clinical Oncology (ASCO) Center for Research and Analytics. She is the staff lead for ASCO’s Research Community Forum, which is a solution-oriented initiative to address clinical trial site challenges with conducting and managing clinical trials. She also represents ASCO on a variety of multi-stakeholder task forces. Patricia has a master’s degree in health research methodology from McMaster University’s Clinical Epidemiology and Biostatistics Department in Ontario, Canada. Her expertise is in research methodology, research implementation, measurement design and evaluation, and data management. Patricia’s career reflects over 20 years of commitment to clinical research and evidence-based quality health care in oncology, pediatric rehabilitation, child and maternal health, and rheumatoid diseases.

Elena Jouravleva, PhD
Director, Research Operations, CRO and Regulatory Affairs, US Oncology Research
Mckesson

Dr. Jouravleva has over 20 years of leadership experience in varying aspects of the life sciences industry and clinical research. She has supported clinical trials working with various pharmaceutical and biotech companies and contributed to approvals by various regulatory agencies, numerous pharmaceutical, diagnostic and device products. Dr. Jouravleva currently supports US Oncology Research, a clinical trial site management organization representing approximately 160 locations across the United States, as the Director of Research Operations overseeing Regulatory Affairs, IRB and the Complimentary CRO services groups. She holds Master of Science and Ph.D. degrees in Biology and focused her thesis on genetics of pathogenesis in Vibrio cholerae.

 

Wenora Y. Johnson
Three-time Cancer Survivor
Patient Advocate

Wenora Y. Johnson is a three-time Cancer survivor, Volunteer Fight CRC  Research/Patient Advocate, caregiver/provider and U.S. Navy veteran. Wenora began working closely with  Fight Colorectal Cancer as a Research  Advocate following her diagnosis of stage 3b colon cancer in 2011.  As a Lynch Syndrome patient, Wenora advocates for genetic testing and awareness. She serves on various panels and review boards to provide extensive feedback on her  role as a patient and research advocate with several organizations. She has written various patient advocate blogs and participated as a guest speaker for the Powerful Patient Podcast.  Wenora works in administration in the greater Chicagoland area and enjoys riding her motorcycle, reading and traveling with her family.

Denise Johnson Sura
Senior Director, Site Engagement
Eli Lilly & Company

 

Denise Johnson Sura joined Eli Lilly and Company in 2004 as a Clinical Research Associate and has since held a variety of positions across the organization supporting the global development of medicines. Presently, Denise leads the global organization responsible for the identification, qualification, support and collaboration with clinical trial sites participating in Lilly studies. Denise and her team recognize the value of site and patient feedback in the design of efficient and effective studies, ultimately leading to improved clinical trial experiences.

Spencer Kalk
Associate Project Director, Oncology & Hematology
Syneos

 

  • 13 years at Syneos Health (Legacy INC Research)
  • 11 years in Oncology with primary focus in Hematologic Malignancies and AML
  • Management and Oversight on 15+ AML Protocols including a large Umbrella Program focused on biomarker based therapies in AML

Maimah Karmo
Founder & CEO
Tigerlily Foundation

Maimah Karmo is the Founder/CEO of the Tigerlily Foundation (Tigerlily) and a twelve-year survivor of breast cancer.   On February 28, 2006, at 4:45 p.m., Maimah was diagnosed with Stage 2 breast cancer. She had no family history and was 32-years old.  While undergoing her second round of chemotherapy, she made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer.  After her second treatment, Tigerlily Foundation was born. 

Tigerlily provides breast health, educational, empowerment wellness and transformational programs to young women.  After working with Congresswoman Debbie Wasserman Schultz to develop the Breast Cancer Education and Awareness Requires Learning Young (EARLY) Act, in October 2011, Maimah was appointed to the Federal Advisory Committee on Breast Cancer in Young Women, a committee established by the Affordable Care Act, on which she works to develop initiatives to increase knowledge of breast health and breast cancer, for women under the age of 45 and those at heightened risk for developing the disease.   She is a speaker and media personality, regularly called upon to speak on Capitol Hill and other venues, as a health, advocacy and empowerment expert.

In 2015, Maimah advocated with Members of Congress to ensure that young women had access to breast screening.  Tigerlily Foundation flew young women to Washington, D.C. to meet with 74 members of Congress.  The visit resulted in doubling the House and Senate support for the Protecting Access to Lifesaving Screening (PALS) legislation.  The bill was signed into law within a month, protecting the lives and rights of millions of women. She is a leader in the women’s health field, creating and implementing national health initiatives for women and girls, with a goal of eliminating disparities of age, stage and color. 

Under Maimah’s leadership, Tigerlily Foundation has launched national and global health initiatives focused on ending disparities, through the #InclusionPledge, partnering with global stakeholders, with a call to action to recognize health disparities as a social justice issue; and working to end disparities for black women in our lifetime. Maimah has appeared in USA Today, U.S. News and World Report, Black Enterprise, Oprah Magazine, Essence Magazine, Ladies Home Journal, Cosmopolitan, Seventeen, Good Housekeeping, Harper’s Bazaar, Marie Claire, Redbook, Women and Cancer, Cure Magazine, Traditional Home Magazine and more. She has also been featured on Fox 5, ABC 7, CBS, the Oprah Winfrey Show, OWN, Good Morning America, the Today Show and more. She is a sought-after speaker by the media and for policy events; and she is a philanthropist.  In 2010, Maimah published Fearless: Awakening to my Life’s Purpose Through Breast Cancer. In 2018, she published the “Badass Girl’s Book of Prayers”.  She recently published Divine Downloads:  Transforming through Trauma, followed by Unicorn Boss, in June 2020.  In 2013, she founded Bliss Magazine, a digital publication that inspires others to live their purpose.

Daniel Kavaugh, PhD, RAC
Senior Scientific Advisor, Gene Therapy
WCG Clinical

Dr. Kavanagh is Senior Scientific Advisor, Gene Therapy at WIRB-Copernicus Group (WCG). Prior to joining WCG, Dr. Kavanagh was Assistant Professor of Medicine and Institutional Biosafety Committee Vice Chair at Harvard Medical School and Assistant Immunologist at the Massachusetts General Hospital.  He was also co-chair of a Phase 1 clinical trial of an autologous mRNA-transfected dendritic cell vaccine in HIV+ subjects.

Dr. Kavanagh holds a PhD in molecular microbiology and immunology from the Oregon Health and Science University and is certified in regulatory affairs (RAC-US) by the Regulatory Affairs Professional Society. He completed his postdoctoral training at Harvard Medical School, Boston MA, and the Rockefeller University, New York, NY.

Allison Kemner, MSN, BSN
Executive Director, Clinical Development
Incyte

Experienced Executive Leader with a demonstrated history working in the pharmaceutical industry.
Passionate about building high performing teams who deliver on shared goals while bringing the voice of patients and caregivers into the development life cycle.

Breadth of experience in biotechnology, life sciences, CRO Management, clinical trial management system (CTMS), and drug development. Research professional with dual MSN’s in Healthcare Business Administration, Health Leadership; Nursing Research and Clinical Nursing earned through University of Pennsylvania School of Nursing and The Wharton School. 

Nicholas Kenny
Chief Scientific Officer
Syneos

Nick has over 21 years of experience in clinical development and consulting.  Passionate about rapidly moving compelling new science for unmet medical needs through the development process to arrive at early and innovative decisions. 

He has been with the company since 2006 where he grew and led the Oncology team until moving to the CSO role in 2018 where he oversees the Medical Team for Syneos Health, the Consortia Models for e.g. Rare Diseases and Cell and Gene Therapies and is a leader on Governance for our Dynamic Assembly of cutting edge data assets.  Drives Thought Leadership for the company.

Nick is also a senior representative to the Clinical Trials Transformation Initiative (CTTI) Steering Committee on behalf of Syneos Health.

His early career was in biomedical research in the UK, US and Canada, and he was on faculty at the University of Vermont Medical School for several years.

 

Moh’d Khushman, MD
Associate Professor, Interdisciplinary Clinical Oncology / Interim Director, Medical Oncology Fellowship Program / Leader, Gastrointestinal Oncology Program
The University of South Alabama, Mitchell Cancer Institute

I am an Associate Professor of Interdisciplinary Clinical Oncology at the University of South Alabama Mitchell Cancer Institute. I am also the Leader of the Gastrointestinal Oncology Program and the Director of the Medical Oncology Fellowship Program.

My clinical interests are focused on GI malignancies especially pancreatic adenocarcinoma. My research efforts are focused in translational research in pancreatic cancers, exosomes and pharmacogenomics. I highly value teaching and mentorship.

I am committed to providing my patients with the most cutting edge and current evidence based treatments in a compassionate and thoughtful manner. I strive to provide hope and I aim for cure when feasible. That is the ultimate success. In my research, I find exploring Mother Nature’s secrets a fascinating and wonderful experience. I see patients at Mitchell Cancer Institute in Mobile, Alabama. I am a member of the American Society of Clinical Oncology (ASCO). I am board certified in Medical Oncology, Hematology and Internal Medicine. 

Deb Kientop, MBA
VP, Oncology Development
synteract®

Deb Kientop, MBA brings over 25 years of experience in oncology drug development, starting in the cancer research labs at the University of Wisconsin, and moving into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, and corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Deb is also a published author and cancer patient advocate.

Prior to joining Synteract, Deb was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma, and Eisai.

Deb holds a Bachelor of Science in Pharmacology and Toxicology, and a Master of Business Administration from the University of Wisconsin.

Andy Kinley, PhD
Global Head, Oncology Strategy, IQVIA Biotech
IQVIA

Clinical researcher with over 20 years combined experience leading basic and clinical research in oncology and hematology. Focused on design and implementation of effective strategies for oncology clinical trials by leveraging deep knowledge of the current regional standards of care, competition, and future direction of the field. Specializing in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines) including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Driven to continually eliminate biases from decision making and develop robust processes for accurate forecasting and planning. 

Jeff Kingsley, EMBA
CEO
IACT Health

Dr. Jeff Kingsley creates imaginative solutions to solve the biggest issues in clinical research. Surrounded by a bold group of individuals who share his vision of a better world, they are structuring IACT Health as an entrepreneurial enterprise capable of revolutionizing the clinical research paradigm in a daring way. This tenacious group of leaders is capable of outstanding results.

Dr. Kingsley is a serial entrepreneur and international speaker, passionate about excellence in everything and in making the world a better place. Jeff received his Bachelor of Science degree with concentrations in biology, chemistry, history, and cultural anthropology, and his Master of Science degree in biochemistry. He then completed his medical degree and went on to complete his MBA several years after founding what is now IACT Health.

Dr. Kingsley has been faculty with a prominent Family Medicine Residency program as well as Director of several academic health system departments. He currently holds faculty appointments with numerous medical schools and continues to enjoy nurturing the next generation of leaders and physicians.

Dr. Kingsley is founder and CEO of IACT Health, a research management organization, and eighteen wholly owned and integrated clinical research offices throughout the Southeast US. The family of companies conduct phase I through IV research in nearly every medical specialty; inpatient and outpatient; pharmaceutical, biotechnology, and medical device. His mission is to create a new paradigm of research that allows brilliant minds to innovate faster and to deliver those new ideas the patients who need them.

Dr. Kingsley is the past Chair of the Board of Trustees for the Association for Clinical Research Professionals which represents more than 13,000 clinical research professionals internationally. He volunteers his time and expertise on numerous other international Boards of Directors.

Lauren Kingston
Associate Director, Clinical Trial Initiation
EQRx

Lauren has over 15 years’ experience in clinical operations working in the Pharmaceutical and CRO sectors with a primary concentration in Global Study Start-up. She has held leadership positions with two large CROs and has extensive experince with driving initiatives that optimize global processes, people, and technology. Lauren is passionate about leveraging analytics to facilitate data-driven decision making to improve operational performance.

Selin Kurnaz, PhD
Co-Founder & CEO
Massive Bio

Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a decade specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Healthcare and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoken extensively about life sciences in tech and how to deliver information in creative ways. Massive Bio is an alumni of eLab and PhilipsHealthworks Precision Cancer Care start-up acceleration programs.

Natalie Lewis
Holistic Health Coach and Meditation Guide
Destinae Wellness

Natalie Lewis is a certified holistic health coach, meditation guide, speaker, facilitator and spiritual advisor who helps men and women find balance in mind, body, and soul through meditation, plant medicine, energy medicine, nutrition, and mindset shifting. Her work began with a desire to first heal her own life which fueled her dedication to continuously learn, grow, and evolve. This personal dedication then became her life’s mission to share her journey of how to create a sustainable health and wellness lifestyle.

Natalie is a Mother to three teen daughters and a USAF Veteran. She resides in Sunny South Florida where you can often find her spending time with her family at the beach.

 

 

Kamala Maddali
Vice President, Strategic Alliances and Collaborations
Deep Lens

Dr. Kamala Maddali is a biotech, pharma, diagnostics, and life sciences executive with over 17 years of deep expertise in Precision Medicine. Prior to Deep Lens, Dr. Maddali served as a chief scientific and commercial executive for many notable Fortune 500 companies like Merck, Quintiles, and Quest Diagnostics in precision medicine. She also served as an executive advisor for several other healthcare technology companies focused on artificial intelligence, blockchain genomics, nutraceuticals, bioinformatics, biotechs focused on unique precision medicine driven solutions. Dr. Maddali has a Ph.D. in Pharmacology from University of Missouri-Columbia and a doctorate in Veterinary Medicine from Tirupati, India. She brings unique experience across precision medicine and education from her personal battle as a “Rare Disease patient” herself. She is an active leader in precision medicine and a patient advocate serving as a board member for several US/International based organizations focused on cancer, rare disease diagnosis and prevention.

 

Marcus Maleck
Director, Global Business Partnerships
Society for Clinical Research Sites (SCRS)

 

 

Marcus is the Director of Global Business Partnerships for the Society for Clinical Research Sites. Marcus has over 10 years of experience in a variety of business development platforms and excels in his ability to create and cultivate client relationships. With a focus on site success in clinical research, Marcus manages exhibits, sponsorships and partnerships for the Society for Clinical Research Sites. His teams and programs have resulted in global growth for SCRS in membership and event attendance across the world. 

Rosemary McQueary, RN, ASN
Director of Research
Quality Cancer Care Alliance

Rosemary is Director of Research at QCCA, a network of 14 community based oncology practices, conducting research in malignant hematology and oncology. She has worked in a variety of positions within Pharma, CROs, and at a large clinical site. Prior to joining QCCA, Rosemary worked in site relationship roles at Parexel and Syneos Health.

Chelsea McCabe, CCRP
Lead Project Manager, Phase I Program Oncology
John Theurer Cancer Center at Hackensack University

I am the Lead Project Manager at the John Theurer Cancer Center at Hackensack University Medical Center, focusing on Phase I Oncology clinical trials. The primary Principal Investigator in my unit is Dr. Martin Gutierrez, Director of Drug Discovery, and Co-Chief of Thoracic Oncology. In 2020 we successfully enrolled over 140 patients onto Phase I/II clinical trials, even with the ongoing COVID-19 pandemic. In the Phase I unit we have over 30 active and enrolling Phase I/II clinical trials. As the lead project manager, I have been charged with creating and implementing the project management role within several of our highest enrolling divisions.

Karen McIntyre, MSc
Executive Director
Syneos Health

Karen has 27 years’ experience in a clinical research organization(CRO) and Site Management Organisation (SMO)in a variety of positions from Study Site coordinator to Senior Project Director. Karen brings extensive experience in variety of therapeutic areas including cardiovascular and metabolic disorder, women’s health, neuroscience and infectious diseases in phase II through phase IV clinical trials.

 With a special interest in site support she has been involved in the development of Site Support Management tools with the goal to improve quality, transparency and compliance across investigative sites since 2005. Karen is also an active member of National Research Ethics Committee.

 

Amanda Miller
Manager, Quality and Development
WCG Clinical

Amanda is the Manager of Quality and Development for WCG PFS Clinical.  She has detailed clinical research experience providing expertise in administrative roles such as budget development/negotiation, coverage analysis development, claims review, and coverage analysis quality assurance.  Her work with a large array of research sites, from large academic medical centers, dedicated research facilities, major medical centers, and community hospitals, provides Amanda with a well-rounded perspective of clinical research and a comprehensive understanding of the administrative needs of clinical research sites. 

Nicole Montgomery
Product Marketing Director, Clinical Trial Financial Mgmt
Medidata Solutions, a Dassault Systèmes company

Clinical research experience with a focus in global investigator payments and technology. Proven leader in process improvement, software implementation, training and operations. Strategic thinker with client relationships at the forefront of decision making. 

Jane E. Myles, Msc
Director, Decentralized Trial
DCT Center of Excellence, Clinical Development Services
Covance

My mission:  Clinical Trials Innovator: Leveraging technology to deliver innovative patient and site-centric trials.  My background is in clinical operations to enable drug development.  My focus is modernizing trials to fit the needs of patients and sites better while ensuring scientific and regulatory rigor.

Patrick Nealon, MBA
EVP, General Oncology
Syneos

Patrick Nealon has 30 years of global clinical development experience in the Pharmaceutical, Biotechnology and Medical Device industries.

Patrick worked in the hospital laboratory (hematology, blood bank, clinical chemistry and microbiology) for 9 years before starting his career in the pharma industry.

Patrick joined Syneos Health in 2019 and is responsible to drive the Oncology business through the creation of appropriate therapeutic strategies and to ensure execution and quality deliverables for our Syneos Health customers.

Seth Nelson, MS
Vice President of Clinical Strategic Solutions and New Product Development
WCG ThreeWire

 

Christopher O’Brien, MBA
SVP Strategic Partnerships
MyHealthTeams

Experienced Vice President of Strategic Partnerships with a history of working in all sides of the healthcare industry. Strong sales professional with a Executive MBA focused in Systems Thinking from Villanova University. Demonstrated success in a variety of healthcare related industries including Pharmaceuticals supporting R&D, ambulatory healthcare networks supporting electronic health record initiatives and acute care health information management. Involved with a variety of non-profit organizations including the MHE Research Foundation. 

Casey Orvin
Honorary President
Society for Clinical Research Sites

Casey Orvin currently serves as Senior VP of Pharmaceutical Relationships for StudyKIK, a full- service patient recruitment and retention technology company, and also as Honorary President of the Society for Clinical Research Sites (SCRS), a global organization representing nearly 10,000 clinical research sites in 47 countries within the pharmaceutical industry.  Orvin began his career leading a large pharmaceutical research site network, Research Solutions.  In 2007, he was recruited to join Clinical Research Advantage/Radiant as Executive Vice President of Business Development and successfully led a network of over 75 research sites conducting clinical trials for pharmaceuticals, vaccines, and medical devices.  Under Orvin’s leadership, several crucial partnerships were formed with major pharmaceutical companies which fueled the company’s rapid growth both geographically and within the medical community.  Orvin facilitated the acquisition of two competitors securing the company’s spot as the largest clinical research site network in the US.  In 2015, Orvin and the executive team at Radiant merged with the largest site network in the world, Synexus.  Under Orvin’s leadership, Synexus continued to expand to 215 global clinical sites in 4 continents and over 15 countries.  Orvin is passionate about representing the site voice within the industry while ensuring every research patient’s journey is a positive one.

As a thought-leader in the industry, Orvin is regularly sought after as a keynote speaker and panelist and is often quoted by the leading publications covering the clinical research landscape.  In 2020, Orvin was recognized in PharmaVoice as one of the 100 Most Inspiring People in the industry.

Cary Passaglia, MSRC
Director, Clinical Research
Lurie Comprehensive Cancer Center of Northwestern University 

Dawn Pittinger, MBA, CHRC, CRCP
Research Billing and Compliance Manager
Moffitt Cancer Center

James Riddle, MCSE, CIP, CPIA, CRQM
Vice President, Research Services & Strategic Consulting
Advarra

Rene Roach
Stage IV colorectal cancer and is a patient at Johns Hopkins University
Patient Advocate

I don’t have COVID-19. But the clinical trial that could save my life has been put on hold due to COVID-19.

My name is Rene Roach. I’m struggling with a recurrence of Stage 4 colorectal cancer in my lymph nodes. It’s a disease that’s likely to kill me without treatment, and surgery, the gold standard of treatments, is not an option for me. I was in a clinical trial. But now that trial has been put on indefinite hold as researchers worldwide join the fight against COVID-19.

I’m not alone. Clinical trials in many other areas have also ceased as researchers race to find a COVID-19 therapy or vaccine. I can still get chemotherapy, but not the clinical trial that had given me hope–of a cure, at best, or anyway enough strength to withstand the rigors of surgery.

Before COVID-19 hit, I was pre-screening for a promising trial at Duke Medical Center. Originally biopsy slides were requested from Johns Hopkins, but after two weeks it was discovered that there was not enough tissue to create the required slides. The research team at Duke reached out to Medstar Hospital to request slides from my original tumor when the trial sponsor, along with many other sponsors of clinical trials in many countries for many serious conditions, brought these trials to a halt. As I write, there is no word on when my trial will reopen.

I hope the chemo I am currently on keeps me stable until this crisis is over. But in some cases clinics are delaying even chemo. I am fortunate beyond words that I am still getting chemo at Johns Hopkins. Without it, my cancer would most likely grow and spread.

There will most likely come a time when my chemo stops working.  With a COVID-19 vaccine perhaps 12-18 months off, many like me will go without the benefits a clinical trial might bring, lingering in an uneasy state of suspended animation.  We as a community need to find a way to open these trials back up.

Issac R. Rodriguez-Chavez, MS, MHS, PhD
Senior Vice President, Scientific and Clinical Affairs
PRA Health Sciences, formerly with the FDA

Dr. Rodriguez-Chavez has more than 32 years of experience in virology, microbiology, immunology, vaccinology and viral oncology, including basic, pre-clinical and clinical research (phase I-IV). Most recently as a Senior Officer for Clinical Research Methodologies, Regulatory Compliance, and Medical Policy Development with the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER), he led the development of guidance around decentralized clinical trials using digital health technologies. With the FDA, he evaluated and modernized clinical research protocols that impact multiple disease areas.

Prior to his work with the FDA, Dr. Rodriguez-Chavez was founder and CEO of 4Biosolutions Consulting and was the Vice President for Research at the Texas Biomedical Research Institute. Before that, he was the Director of the AIDS & Immunosuppression Program at the National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH). Dr. Rodriguez-Chavez also held the position of Senior Clinical Scientist at Schering Plough Corporation and the Director of a portfolio for HIV Vaccines at the National Institutes of Allergy and Infectious Diseases, NIH.

 

Archana Sah, MSc(Pharm), PMP 
Vice President, Head of Clinical Operations, Tizona Therapeutics
Tizona Therapeutics
Chair, SCRS Oncology Program

 

Archana Sah is a clinical development thought leader with 22+ years’ experience and passion for developing medicines for patients having led and contributed to 15 FDA/EMEA drug approvals in Oncology, Immuno-Oncology, Precision Therapeutics, Rare Diseases, Metabolic Diseases and Women’s Health. She has held various global positions within Biotech, Big pharma and Oncology startup companies and in the last five years she has led/contributed to 10 drugs from research to approvals in the Oncology and Immuno-oncology space at Genentech/Roche. She is currently Vice President, Head of Clinical Operations with Tizona Therapeutics, a company focused on improving outcomes for cancer patients by translating novel scientific insights into developing first-in-class immunotherapies. 

She has led highly matrixed, cross-functional teams to create value and deliver strategy and execution with several molecules in Phase I-III development through approvals. Archana is recognized as a strategic expert on emerging topics ranging from therapeutic landscape/treatment trends expertise to thought leader relationship management. Her passion is to develop high-performing teams and create inclusive, empowering and diverse cultures focused on accountability and customer-centric mindset. 

Ms. Sah also chairs the Society for Clinical Research Sites Oncology Board with a vision to cure cancer through efficiency in process and strength in the relationships between clinical research sites, pharmaceutical companies, oncology vendors and patients. She provides direction and guidance for the vision, mission and three strategic workstreams for the Board.  Ms. Sah also serves as a member of American Cancer Society Cancer Action Network workstreams on Barriers to Clinical Trial Enrollment Implementation and Clinical Trial Matching.

She holds patents, publications, performance awards, and is often an invited speaker at several industry conferences. Ms. Sah received her Master’s in Pharmaceutical Sciences from University of Cincinnati, College of Pharmacy and a Bachelors in Pharmacy from M. S. University in India.

Fabian Sandoval, MD
CEO & Research Director
Emerson Clinical Research Institute

Dr. Fabian Sandoval, CEO & Research Director, has over 25 years of bench to bedside research experience. His diversified research career has been in academia, healthcare systems and the public sector. He received his Bachelors of Science in molecular and cellular biology from Marymount University, and his Doctorate of Medicine from the Autonomous University of Guadalajara, School of Medicine.

Before opening the doors to Emerson Clinical Research Institute (ECRI) Dr. Sandoval’s research activities have included bench research at the National Institutes of Neurological Disorders and Stroke (NINDS) where he focused his work on Early Onset Alzheimer’s Disease, and Cretzfelt-Jakob Disease. At the NIHs’ Clinical Center conducting research in the outpatient Oncology unit, followed by his successful support of an NIH RO1 grant on preventing epilepsy in post-traumatic brain injury patients in adults and children, simultaneously run at the Washington Hospital Center, and Children’s National Medical Center.

Dr. Sandoval served as the Supervisory Research Integrity & Compliance Officer in the Army Human Research Protections Office in the Office of the Army Surgeon General. Responsibilities included establishment, and oversight of Human Research Protection Programs across Army commands. His input has been instrumental in the review, development, and selection of protocols, in addition to education and training for resident and hospital faculty.

 

Alain Sayegh, MBA, MHA
CEO
Renovatio Clinical

Alain Sayegh serves as Chief Operating Officer for Renovatio Clinical. With 10+ years of experience in basic and clinical research, from academia to private, he is able to provide subject level expertise on various aspects of the business. In collaboration with our network, he has been able to identify strategic initiatives and partnerships that will facilitate the growth and viability of the organization. Alain holds a Bachelors of Science and a Masters in Business and Healthcare Administration.

Earl Seltzer
Senior Director
Covance

Earl has over 15 years of industry experience, 7 years at 2 research sites as a study coordinator then in operations/business development and 8 years in the CRO space working in feasibility and therapeutic strategy. He has spoken at various industry conferences on CRO-site relations, feasibility best practices, use of real world data in feasibility, and pediatric/rare disease feasibility. Earl’s special interests are in site relationships, real world data, optimizing feasibility, biomarker driven trial enrollment, and pediatric clinical trials.

Allyson Small
Chief Operating Officer
Society for Clinical Research Sites (SCRS)

Allyson Small is Chief Operating Officer of the Society for Clinical Research Sites (SCRS). With nearly 20 years of experience working in the healthcare industry, Small joined the SCRS team in 2013. She plays an integral role in strategic growth, developing key partnerships, and increasing global membership by 80%. Small also oversees all development and production of 4 International Summits.

Small is a champion for creating a voice for clinical research sites across the globe and assuring site sustainability. She is an active community member and dedicated volunteer in the Annapolis area where she lives with her husband and three children.

Sandy Smith, RN, MSN, AOCN
Senior Vice President, Clinical Solutions and Strategic Partnerships
WCG

As Senior Vice President, Clinical Solutions and Strategic Partnerships for WCG, Sandy Smith, RN, MSN, AOCN, strategically aligns clinical solutions to support sites to enhance their clinical trials processes. Sandy is an oncology-focused healthcare leader who has held diverse roles in corporate, community-based practice and hospital settings. She has spent her career partnering with physicians and other healthcare stakeholders to drive customer value and clinical excellence in patient-centric oncology services. Prior to WCG, she was Vice President of US Oncology Research, an oncology-specific site management organization of independent practices and hospital-based research programs. Sandy was responsible for developing strategic partnerships with sponsors and sites to expand clinical trials services in early and late phase trials and launched a gene and cell therapy program. She worked with more than 1,000 investigators and their site staff to integrate lean six sigma processes and technology solutions to redesign clinical trial workflows for operational efficiency, reduced study start-up times, and data integrity.

Sean Soth
VP, Business Partnerships
Society for Clinical Research Sites

“Site success impacts everyone in research” is the mission that drives Sean and his team as Vice President of Business Partnerships for SCRS. With more than 15 years experience in clinical business development and a background in association management, Sean works to connect sponsors, CROs and solution providers within the SCRS community.

R’kes Starling, RPh, MBA
President & CEO
Reveles Clinical Services

As CEO and Founder of Reveles Clinical Services, R’Kes has over 18 years providing high-touch pharmacy services, clinical reach operations, specialty drug distribution, and clinical management to patients with rare and complex diseases such as Autoimmune, Kidney disease, Cancer, Hemophilia, and Cystic Fibrosis.

Prior to founding Reveles, R’Kes headed up the Specialty Pharmacy and Clinical Research Service business at McKesson, which is a “central depot” that provides investigational product distribution, accountability, and storage for the US Oncology Network. R’Kes oversaw a multi-disciplinary clinical research team involved in over 130 active oncology-focused clinical trials and was responsible for delivering over 50,000 annual shipments of investigational products, laboratory kits, and clinical supplies to the US Oncology network sites across the United States. Prior to McKesson, as the Vice President of Operations, he previously oversaw eight Home Infusion specialty pharmacies in six states with Coram CVS Specialty Infusion Services, which has translated into R’Kes having in-depth experience and knowledge of providing decentralized clinical trial support and direct-to-patient care for thousands of patients on clinical trials and commercially-approved medications with complex and rare diseases in their homes.

Prior to Coram, R’Kes held various management roles with DaVita, Inc., a Fortune 500 Dialysis services provider. Before the dialysis industry, Mr. Starling has worked in the retail pharmacy operations management at Wal-Mart, Sam’s Club, and Target Stores.

Additionally, R’Kes have consulted and worked collaboratively with over 30 biopharmaceutical companies on pre-launch to commercialization development, launch strategies, and patient access programs for new specialty pharmaceutical therapies. 

R’Kes received his Bachelor of Science in Pharmacy from Purdue University and his Executive MBA from Kellogg School of Management, Northwestern University.

 

 

Amanda Steenbergen, CCRP
Sr. Director, Global Clinical Training
WCG Trifecta

Amanda has over 20 years of biopharma experience, including over 8 years of clinical site experience as a certified clinical research coordinator. In 2015, Amanda transitioned from the clinical research site space to the pharma/CRO space where she was responsible for training strategy development and delivery of Investigator Site training, in cooperation with the cross-functional clinical operations teams at Eli Lilly. In her current role as the Sr. Director of Global Clinical Training, she serves as a liaison between clients and internal teams in establishing best practices for clinical trial training, including developing training content in collaboration with sponsors and research industry key opinion leaders. 

Wendy Tate, PhD, MS, GStat
Director, Research Operations
Advarra

Wendy Tate, PhD, MS, GStat, is the Director of Research Operations at Advarra. Wendy’s work is focused on the evaluation of clinical research operations, including the development and testing of quantitative methods to measure and assess protocol feasibility, study activation, and workload. Her passion is to provide helpful and meaningful processes and tools to clinical research professionals that streamline clinical research practices and better the clinical research enterprise as a whole. Prior to Advarra, Wendy spent 15 years at the University of Arizona in various roles within human laboratory, human subjects protection, and clinical research roles, including leadership roles with the IRB and Cancer Center clinical trials office. She received her MS in Applied Biosciences and PhD in Pharmaceutical Sciences with an emphasis in Pharmaceutical Economics, Policy, and Outcomes and a minor in Epidemiology from the UA.

 

 

Andy Taylor, J.D. Law
Senior Manager of Clinical Operations
PRA Health Sciences

Andy Taylor joined PRA in October 2012 and has worked in various departments including Contracts/Legal, Study Startup, Study Startup Management.  Andy currently manages a team of individuals specializing in Startup Project Management overseeing all phases of Study Startup.  Andy lives in the Wilmington, NC area with his wife and two daughters. 

Mary-Anne Tomas, CCRA
Director Site Intelligence & Selection
Pfizer

Superior knowledge of clinical research, phase I to phase IV trials, ICH/GCP, federal and provincial regulations and guidelines. Excellent leadership skills and ability to effectively manage multidisciplinary teams. Strong analytical, planning, and budget management skills, combined with the ability to coordinate the efforts of many to meet organizational goals. Productive and efficient with a proven ability to work independently. Self-motivator with high energy. 

 

 

Elizabeth Verderber
Senior Manager, Clinical Operations
PRA Health Sciences

Elizabeth Verderber has been in the CRO industry since 2004.  She has worked as a Research Assistant, Clinical Research Associate, Clinical Team Manager and now is a part of leadership for clinical management.  Throughout her entire clinical research career Elizabeth has been working in the oncology space including managing oncology and hematology studies from a clinical perspective.  Elizabeth has been in her current role in clinical management at PRA for 5 years. 

Gene Vinson
Executive Director, Global Data Technologies, Biometrics
Syneos Health

Gene Vinson has over 15 years’ experience in a clinical research organization (CRO) and is currently the Senior Director of Global Data Technologies in Biometrics at Syneos Health. Gene has lead the implementation of multiple EDC Systems and is an expert in the implementation of Electronic Data Capture. Gene is currently working with eSource systems and the integration of Electronic Health Record data into EDC systems and the integration of clinical data into the Syneos Health Data Lake. 

Julia Yegorova
Science Lead for Advancing Health Equity
Genentech

I am personally and professionally committed to advancing health equity globally. I partner across business to address barriers to quality, equitable healthcare access. I partner across the pharma industry on diversity working groups and connect siloed efforts within Roche and Genentech. I am a core member of our Diversity and Inclusion team, Power of Leadership team, a Mindfulness facilitator and marketing manager, and a Mental Health Champion. I analyze problems and build close relationships with stakeholders to develop solutions. I am tirelessly passionate about the mission to enable personalization of healthcare and put each patient at the center of their health management.

REGISTER NOW